Full eradication of pre-clinical human papilloma virus-induced tumors by a lentiviral vaccine

Archive ouverte

Douguet, Laëtitia | Fert, Ingrid | Lopez, Jodie | Vesin, Benjamin | Le Chevalier, Fabien | Moncoq, Fanny | Authié, Pierre | Nguyen, Trang‐my | Noirat, Amandine | Névo, Fabien | Blanc, Catherine | Bourgine, Maryline | Hardy, David | Anna, François | Majlessi, Laleh | Charneau, Pierre

Edité par CCSD ; Wiley Open Access -

International audience. Human papillomavirus (HPV) infections are the cause of all cervical and numerous oropharyngeal and anogenital cancers. The currently available HPV vaccines, which induce neutralizing antibodies, have no therapeutic effect on established tumors. Here, we developed an immuno-oncotherapy against HPV-induced tumors based on a non-integrative lentiviral vector encoding detoxified forms of the Early E6 and E7 oncoproteins of HPV16 and 18 genotypes, namely, "Lenti-HPV-07". A single intramuscular injection of Lenti-HPV-07 into mice bearing established HPV-induced tumors resulted in complete tumor eradication in 100% of the animals and was also effective against lung metastases. This effect correlated with CD8 + T-cell induction and profound remodeling of the tumor microenvironment. In the intra-tumoral infiltrates of vaccinated mice, the presence of large amounts of activated effector, resident memory, and transcription factor T cell factor-1 (TCF-1) + "stem-like" CD8 + T cells was associated with full tumor eradication. The Lenti-HPV-07-induced immunity was long-lasting and prevented tumor growth after a late re-challenge, mimicking tumor relapse. Lenti-HPV-07 therapy synergizes with an anticheckpoint inhibitory treatment and therefore shows promise as an immuno-oncotherapy against established HPV-mediated malignancies.

Suggestions

Du même auteur

An intranasal lentiviral booster reinforces the waning mRNA vaccine-induced SARS-CoV-2 immunity that it targets to lung mucosa

Archive ouverte | Vesin, Benjamin | CCSD

International audience. As the coronavirus disease 2019 (COVID-19) pandemic continues and new severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern emerge, the adaptive immunity initially ...

Brain Cross‐Protection against SARS‐CoV‐2 Variants by a Lentiviral Vaccine in New Transgenic Mice

Archive ouverte | Ku, Min-Wen | CCSD

International audience. COVID-19 vaccines already in use or in clinical development may have reduced efficacy against emerging SARS-CoV-2 variants. In addition, although the neurotropism of SARS-CoV-2 is well establ...

T-cell immunity induced and reshaped by an anti-HPV immuno-oncotherapeutic lentiviral vector

Archive ouverte | Fert, Ingrid | CCSD

International audience. Werecently developed animmuno-oncotherapy against human papillomavirus (HPV)-induced tumorsbased on a lentiviral vector encoding the Early E6 and E7 oncoproteins of HPV16 and HPV18genotypes, ...

Chargement des enrichissements...